Exact Mass: 703.5903132
Exact Mass Matches: 703.5903132
Found 433 metabolites which its exact mass value is equals to given mass value 703.5903132,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
PE(P-18:0/16:0)
C39H78NO7P (703.5515607999998)
PE(P-18:0/16:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:0/16:0), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of palmitic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:0/16:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:0/16:0), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of palmitic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(15:0/P-16:0)
C39H78NO7P (703.5515607999998)
PC(15:0/P-16:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(15:0/P-16:0), in particular, consists of one chain of pentadecanoic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The pentadecanoic acid moiety is derived from dairy products and milk fat, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(15:0/P-16:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(15:0/P-16:0), in particular, consists of one chain of pentadecanoic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The pentadecanoic acid moiety is derived from dairy products and milk fat, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(16:0/P-18:0)
C39H78NO7P (703.5515607999998)
PE(16:0/P-18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(16:0/P-18:0), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(16:0/P-18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(16:0/P-18:0), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(18:0/P-16:0)
C39H78NO7P (703.5515607999998)
PE(18:0/P-16:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:0/P-16:0), in particular, consists of one chain of stearic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The stearic acid moiety is derived from animal fats, coco butter and sesame oil, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PE(O-16:0/18:1(9Z))
C39H78NO7P (703.5515607999998)
2-(9Z-octadecanoyl)-1-hexadecyl-sn-glycero-3-phosphoethanolamine is an ether lipid. Ether lipids are lipids in which one or more of the carbon atoms on glycerol is bonded to an alkyl chain via an ether linkage, as opposed to the usual ester linkage. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. 2-(9Z-octadecanoyl)-1-hexadecyl-sn-glycero-3-phosphoethanolamine is an ether lipid. Ether lipids are lipids in which one or more of the carbon atoms on glycerol is bonded to an alkyl chain via an ether linkage, as opposed to the usual ester linkage.
PC(P-16:0/15:0)
C39H78NO7P (703.5515607999998)
PC(P-16:0/15:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-16:0/15:0), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of pentadecanoic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the pentadecanoic acid moiety is derived from dairy products and milk fat. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(P-16:0/15:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-16:0/15:0), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of pentadecanoic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the pentadecanoic acid moiety is derived from dairy products and milk fat. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(P-16:0/18:0)
C39H78NO7P (703.5515607999998)
PE(P-16:0/18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-16:0/18:0), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of stearic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the stearic acid moiety is derived from animal fats, coco butter and sesame oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-16:0/18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-16:0/18:0), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of stearic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the stearic acid moiety is derived from animal fats, coco butter and sesame oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
Phosphatidylethanolamine alkyl 16:0-18:1
C39H78NO7P (703.5515607999998)
Phosphatidylethanolamine alkenyl 18:0-16:0
C39H78NO7P (703.5515607999998)
(2-aminoethoxy)[2-(hexadecanoyloxy)-3-[octadec-1-en-1-yloxy]propoxy]phosphinic acid
C39H78NO7P (703.5515607999998)
PE(O-16:0/18:1)
C39H78NO7P (703.5515607999998)
Lecithin
C39H78NO7P (703.5515607999998)
PE(34:0)
C39H78NO7P (703.5515607999998)
PC(O-16:0/15:1(9Z))
C39H78NO7P (703.5515607999998)
PC(P-18:0/13:0)
C39H78NO7P (703.5515607999998)
PE(O-20:0/14:1(9Z))
C39H78NO7P (703.5515607999998)
PE(O-18:0/16:1(9Z))
C39H78NO7P (703.5515607999998)
PE(P-20:0/14:0)
C39H78NO7P (703.5515607999998)
1-O-(alpha-D-galactopyranosyl)-N-tetracosanyl-2-aminononane-1,3,4-triol
A glycophytoceramide comprising (2S,3S,4R)-2-aminononane-1,3,4-triol having an alpha-D-galctopyranosyl residue at the O-1 position and an tetracosanoyl group attached to the nitrogen.
PC O-31:1
C39H78NO7P (703.5515607999998)
PE O-34:1
C39H78NO7P (703.5515607999998)
N-[2-[[[[(2S,3R)-2-(Hexadecanoylamino)-3-hydroxy-4-octadecenyl]oxy]hydroxyphosphinyl]oxy]ethyl]trimethylaminium
C39H80N2O6P+ (703.5753690000001)
2-[[(2S,3R)-2-[[(Z)-hexadec-9-enoyl]amino]-3-hydroxyoctadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
N-hexadecanoyl-1-O-beta-D-glucosyl-4-hydroxy-15-methylhexadecasphinganine
1-(1Z-octadecenyl)-sn-glycero-3-phospho-(N-palmitoyl)ethanolamine
C39H78NO7P (703.5515607999998)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-(octadecanoylamino)hexadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E,2S,3R)-2-(heptadecanoylamino)-3-hydroxyheptadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E,2S,3R)-2-(heptadecanoylamino)-3-hydroxy-15-methylhexadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(2S,3R)-2-(hexadecanoylamino)-3-hydroxyoctadec-5-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] icosanoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexadecoxypropan-2-yl] (Z)-octadec-9-enoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-octadec-9-enoxy]propan-2-yl] hexadecanoate
C39H78NO7P (703.5515607999998)
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-tetratriacont-23-enoate
C39H78NO7P (703.5515607999998)
(11Z,14Z,17Z,20Z,23Z,26Z,29Z,32Z,35Z)-N-(1,3-dihydroxynonan-2-yl)octatriaconta-11,14,17,20,23,26,29,32,35-nonaenamide
(14Z,17Z,20Z,23Z,26Z,29Z,32Z,35Z)-N-[(E)-1,3-dihydroxynon-4-en-2-yl]octatriaconta-14,17,20,23,26,29,32,35-octaenamide
[2-[(Z)-docos-13-enoyl]oxy-3-nonoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
(7Z,10Z,13Z,16Z,19Z,22Z,25Z)-N-[(4E,8E)-1,3-dihydroxynonadeca-4,8-dien-2-yl]octacosa-7,10,13,16,19,22,25-heptaenamide
(6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z)-N-[(E)-1,3-dihydroxyheptadec-4-en-2-yl]triaconta-6,9,12,15,18,21,24,27-octaenamide
(9Z,12Z,15Z,18Z,21Z,24Z,27Z)-N-[(4E,8E)-1,3-dihydroxyheptadeca-4,8-dien-2-yl]triaconta-9,12,15,18,21,24,27-heptaenamide
(8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z)-N-[(E)-1,3-dihydroxypentadec-4-en-2-yl]dotriaconta-8,11,14,17,20,23,26,29-octaenamide
(10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z)-N-[(E)-1,3-dihydroxytridec-4-en-2-yl]tetratriaconta-10,13,16,19,22,25,28,31-octaenamide
(14Z,17Z,20Z,23Z,26Z,29Z)-N-[(4E,8E,12E)-1,3-dihydroxypentadeca-4,8,12-trien-2-yl]dotriaconta-14,17,20,23,26,29-hexaenamide
(11Z,14Z,17Z,20Z,23Z,26Z,29Z)-N-[(4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]dotriaconta-11,14,17,20,23,26,29-heptaenamide
(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-N-[(4E,8E)-1,3-dihydroxyhenicosa-4,8-dien-2-yl]hexacosa-5,8,11,14,17,20,23-heptaenamide
(9Z,12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z)-N-(1,3-dihydroxyundecan-2-yl)hexatriaconta-9,12,15,18,21,24,27,30,33-nonaenamide
(13Z,16Z,19Z,22Z,25Z,28Z,31Z)-N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]tetratriaconta-13,16,19,22,25,28,31-heptaenamide
(5Z,8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z)-N-(1,3-dihydroxypentadecan-2-yl)dotriaconta-5,8,11,14,17,20,23,26,29-nonaenamide
(6Z,9Z,12Z,15Z,18Z,21Z)-N-[(4E,8E,12E)-1,3-dihydroxytricosa-4,8,12-trien-2-yl]tetracosa-6,9,12,15,18,21-hexaenamide
(7Z,10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z)-N-(1,3-dihydroxytridecan-2-yl)tetratriaconta-7,10,13,16,19,22,25,28,31-nonaenamide
(4Z,7Z,10Z,13Z,16Z,19Z)-N-[(4E,8E,12E)-1,3-dihydroxypentacosa-4,8,12-trien-2-yl]docosa-4,7,10,13,16,19-hexaenamide
(8Z,11Z,14Z,17Z,20Z,23Z)-N-[(4E,8E,12E)-1,3-dihydroxyhenicosa-4,8,12-trien-2-yl]hexacosa-8,11,14,17,20,23-hexaenamide
(12Z,15Z,18Z,21Z,24Z,27Z)-N-[(4E,8E,12E)-1,3-dihydroxyheptadeca-4,8,12-trien-2-yl]triaconta-12,15,18,21,24,27-hexaenamide
(10Z,13Z,16Z,19Z,22Z,25Z)-N-[(4E,8E,12E)-1,3-dihydroxynonadeca-4,8,12-trien-2-yl]octacosa-10,13,16,19,22,25-hexaenamide
(12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z)-N-[(E)-1,3-dihydroxyundec-4-en-2-yl]hexatriaconta-12,15,18,21,24,27,30,33-octaenamide
3-Hydroxy-2-(2-hydroxyicosanoylamino)icosane-1-sulfonic acid
3-Hydroxy-2-(2-hydroxyhexadecanoylamino)tetracosane-1-sulfonic acid
3-Hydroxy-2-(2-hydroxyoctadecanoylamino)docosane-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-octacos-17-enoxy]propan-2-yl] hexanoate
C39H78NO7P (703.5515607999998)
3-Hydroxy-2-(2-hydroxypentadecanoylamino)pentacosane-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] (Z)-hexacos-15-enoate
C39H78NO7P (703.5515607999998)
3-Hydroxy-2-(2-hydroxynonadecanoylamino)henicosane-1-sulfonic acid
3-Hydroxy-2-(2-hydroxyheptadecanoylamino)tricosane-1-sulfonic acid
3-Hydroxy-2-(2-hydroxydocosanoylamino)octadecane-1-sulfonic acid
3-Hydroxy-2-(2-hydroxyhenicosanoylamino)nonadecane-1-sulfonic acid
3-Hydroxy-2-(2-hydroxytricosanoylamino)heptadecane-1-sulfonic acid
3-Hydroxy-2-(2-hydroxypentacosanoylamino)pentadecane-1-sulfonic acid
3-Hydroxy-2-(2-hydroxytetracosanoylamino)hexadecane-1-sulfonic acid
3-Hydroxy-2-(2-hydroxytetradecanoylamino)hexacosane-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexacos-15-enoxy]propan-2-yl] octanoate
C39H78NO7P (703.5515607999998)
3-Hydroxy-2-(2-hydroxyhexacosanoylamino)tetradecane-1-sulfonic acid
[3-[(Z)-hexacos-15-enoxy]-2-pentanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[2-heptanoyloxy-3-[(Z)-tetracos-13-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[3-[(Z)-octacos-17-enoxy]-2-propanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[3-[(Z)-docos-13-enoxy]-2-nonanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentadecoxypropan-2-yl] (Z)-nonadec-9-enoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptadecoxypropan-2-yl] (Z)-heptadec-9-enoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-henicos-11-enoxy]propan-2-yl] tridecanoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] henicosanoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-nonadec-9-enoxy]propan-2-yl] pentadecanoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetracos-13-enoxy]propan-2-yl] decanoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-nonadecoxypropan-2-yl] (Z)-pentadec-9-enoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-heptadec-9-enoxy]propan-2-yl] heptadecanoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] (Z)-docos-13-enoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-icos-11-enoxy]propan-2-yl] tetradecanoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-henicosoxypropan-2-yl] (Z)-tridec-9-enoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-decoxypropan-2-yl] (Z)-tetracos-13-enoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tridecoxypropan-2-yl] (Z)-henicos-11-enoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-icosoxypropan-2-yl] (Z)-tetradec-9-enoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] nonadecanoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-docos-13-enoxy]propan-2-yl] dodecanoate
C39H78NO7P (703.5515607999998)
[3-[(Z)-heptadec-9-enoxy]-2-tetradecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[2-[(Z)-hexadec-9-enoyl]oxy-3-pentadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[2-hexadecanoyloxy-3-[(Z)-pentadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[2-octadecanoyloxy-3-[(Z)-tridec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[2-[(Z)-icos-11-enoyl]oxy-3-undecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[3-dodecoxy-2-[(Z)-nonadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[2-decanoyloxy-3-[(Z)-henicos-11-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[3-heptadecoxy-2-[(Z)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[3-[(Z)-icos-11-enoxy]-2-undecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[3-decoxy-2-[(Z)-henicos-11-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[2-dodecanoyloxy-3-[(Z)-nonadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[2-[(Z)-octadec-9-enoyl]oxy-3-tridecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-octadec-1-enoxy]propan-2-yl] hexadecanoate
C39H78NO7P (703.5515607999998)
2-[[(E)-2-(hexadecanoylamino)-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
[2-[(Z)-heptadec-9-enoyl]oxy-3-tetradecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[3-[(Z)-hexadec-9-enoxy]-2-pentadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[2-heptadecanoyloxy-3-[(Z)-tetradec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[3-hexadecoxy-2-[(Z)-pentadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octadecoxypropan-2-yl] (Z)-hexadec-9-enoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tetradecoxypropan-2-yl] (Z)-icos-11-enoate
C39H78NO7P (703.5515607999998)
[3-octadecoxy-2-[(Z)-tridec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[3-[(Z)-octadec-9-enoxy]-2-tridecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoxy]propan-2-yl] octadecanoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexadecoxypropan-2-yl] (Z)-octadec-4-enoate
C39H78NO7P (703.5515607999998)
O-[[[(2R,3S,4E)-2-(Palmitoylamino)-3-hydroxy-4-octadecenyl]oxy]phosphonyl]choline
C39H80N2O6P+ (703.5753690000001)
[(2S)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-icos-1-enoxy]propan-2-yl] tetradecanoate
C39H78NO7P (703.5515607999998)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-(tetradecanoylamino)icos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(2S,3R)-2-[[(E)-hexadec-9-enoyl]amino]-3-hydroxyoctadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
[(2S)-3-[(E)-icos-1-enoxy]-2-undecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
2-[hydroxy-[(2S,3R)-3-hydroxy-2-[[(E)-icos-11-enoyl]amino]tetradecoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-octadec-1-enoxy]propan-2-yl] hexadecanoate
C39H78NO7P (703.5515607999998)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-(pentadecanoylamino)nonadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E,2S,3R)-2-(heptadecanoylamino)-3-hydroxyheptadec-8-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-(nonadecanoylamino)pentadec-8-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-(icosanoylamino)tetradec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E,2R,3S)-3-hydroxy-2-(tridecanoylamino)henicos-8-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E,2R,3S)-2-(dodecanoylamino)-3-hydroxydocos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
[(2S)-3-[(E)-octadec-1-enoxy]-2-tridecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
2-[[(E,2R,3S)-2-(dodecanoylamino)-3-hydroxydocos-8-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-(octadecanoylamino)hexadec-8-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-hexadec-1-enoxy]propan-2-yl] octadecanoate
C39H78NO7P (703.5515607999998)
2-[[(E,2S,3R)-2-(hexadecanoylamino)-3-hydroxyoctadec-8-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(2S,3R)-2-[[(E)-heptadec-9-enoyl]amino]-3-hydroxyheptadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-(pentadecanoylamino)nonadec-8-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-(icosanoylamino)tetradec-8-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(2S,3R)-3-hydroxy-2-[[(E)-octadec-9-enoyl]amino]hexadecoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E,2R,3S)-3-hydroxy-2-(tridecanoylamino)henicos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-(nonadecanoylamino)pentadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
[(2R)-3-[(E)-hexadec-1-enoxy]-2-pentadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-(tetradecanoylamino)icos-8-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(tetradecanoylamino)icos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]icosoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(Z)-icos-11-enoyl]amino]tetradecoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]nonadecoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(Z)-nonadec-9-enoyl]amino]pentadecoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(pentadecanoylamino)nonadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[2-[[(Z)-hexadec-7-enoyl]amino]-3-hydroxyoctadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(icosanoylamino)tetradec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E)-2-(dodecanoylamino)-3-hydroxydocos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(octadecanoylamino)hexadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[2-[[(Z)-dodec-5-enoyl]amino]-3-hydroxydocosoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E)-2-(heptadecanoylamino)-3-hydroxyheptadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(Z)-octadec-11-enoyl]amino]hexadecoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(Z)-tridec-8-enoyl]amino]henicosoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(tridecanoylamino)henicos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(nonadecanoylamino)pentadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E)-2-(decanoylamino)-3-hydroxytetracos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E)-2-(docosanoylamino)-3-hydroxydodec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[2-[[(Z)-henicos-11-enoyl]amino]-3-hydroxytridecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[2-[[(Z)-hexadec-9-enoyl]amino]-3-hydroxyoctadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(Z)-tetracos-13-enoyl]amino]decoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(pentanoylamino)nonacos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]henicosoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(tricosanoylamino)undec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[2-[[(Z)-docos-13-enoyl]amino]-3-hydroxydodecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E)-2-(hexanoylamino)-3-hydroxyoctacos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[2-[[(Z)-hexacos-15-enoyl]amino]-3-hydroxyoctoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E)-2-(heptanoylamino)-3-hydroxyheptacos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(propanoylamino)hentriacont-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E)-2-(butanoylamino)-3-hydroxytriacont-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(pentacosanoylamino)non-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E)-2-acetamido-3-hydroxydotriacont-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E)-2-(henicosanoylamino)-3-hydroxytridec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(nonanoylamino)pentacos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[2-[[(Z)-heptadec-9-enoyl]amino]-3-hydroxyheptadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E)-2-(hexacosanoylamino)-3-hydroxyoct-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(octanoylamino)hexacos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(Z)-octadec-9-enoyl]amino]hexadecoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(tetracosanoylamino)dec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(undecanoylamino)tricos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
1-(1Z-octadecenyl)-2-hexadecanoyl-sn-glycero-3-phosphoethanolamine
C39H78NO7P (703.5515607999998)
A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine in which the alkyl and the acyl groups at positions 1 and 2 are specified as (1Z)-octadecenyl and hexadecanoyl respectively.
1-Pentadecanoyl-2-(1-enyl-palmitoyl)-sn-glycero-3-phosphocholine
C39H78NO7P (703.5515607999998)
MePC(30:1)
C39H78NO7P (703.5515607999998)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Hex1Cer(33:0)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
dMePE(32:1)
C39H78NO7P (703.5515607999998)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved